[1]NOTE:
As provided in LFC policy, this report is intended only for use by the
standing finance committees of the legislature. The Legislative
Finance Committee does not assume responsibility for the accuracy of the information
in this report when used in any other situation.
Only the most recent
FIR version (in HTML & Adobe PDF formats) is available on the Legislative
Website. The Adobe PDF version includes
all attachments, whereas the HTML version does not. Previously issued FIRs and attachments may be obtained from the
LFC’s office in Suite 101 of the State Capitol Building North.
SPONSOR: |
Feldman |
DATE TYPED: |
02/08/02 |
HB |
|
||
SHORT TITLE: |
Fair Market Drug Pricing Act |
SB |
238/aSPAC |
||||
|
ANALYST: |
Dunbar |
|||||
APPROPRIATION
Appropriation
Contained |
Estimated
Additional Impact |
Recurring or Non-Rec |
Fund Affected |
||
FY02 |
FY03 |
FY02 |
FY03 |
|
|
|
|
$0.1 |
See Narrative |
|
|
(Parenthesis ( ) Indicate Expenditure Decreases)
Relates to HB264, SB226,
HB200, SB091, HJM41, SB253, SJM23, HB149, SB263, HJM021,
SJM35, SJM22, and SB118
Human Services Department (HSD)
Health Policy Commission (HPC)
Attorney General (AG)
SUMMARY
Synopsis
of SPAC Amendment
The amendment in Section 3 of the bill provides for the secretary of
the department to negotiate discount prices or rebates for prescription drugs
manufactures to include (1) supplemental rebates for the Medicaid program over
and above those require under 42 U.S.C.
1396r-8 or (2) discount prices or rebates for the discount card
program. The bill strikes language
indicating that the secretary should negotiate discounts prices or rebates for
prescription drugs for any other state programs. In the same section referencing “prior authorization lists”
the secretary of the department is given the discretion to place or take actions involving prior
authorization or formularies for other state programs.
In Section 9 of the bill the secretary of the
department is given the discretion to combine drug-pricing negotiations to
maximize drug rebates when the secretary finds that it is beneficial to both
the discount card program and another state program including the Medicaid
program.
Synopsis
of Original Bill
Senate Bill 238 enacts the “Fair Market Drug Pricing Act.” This Act requires negotiated discount prices or rebates from drug manufacturers or labelers that are better than those required under federal law. The bill also establishes a discount prescription drug program for New Mexico residents who are eligible for participation in the federal Medicare program, or have a family income level below 300% of the federal poverty level. Eligibility is also extended to those individual who are eligible for assistance under the state Medicaid program, or are covered by private insurance programs that provide benefits for prescription drugs equal to or greater than the benefits provided under the discount program. Requires the Secretary of Human Services to negotiate the discount prescription prices with drug manufacturers and labelers and to consider whether to place manufacturers or labelers products on the Medicaid prior authorization list and all other state-funded prior authorization lists based upon the results of the discount negotiation. Requires the Human Services Department to establish the discount card program.
Significant
Issues
This proposed program appears similar to the program implemented in Florida. The Florida program was unsuccessfully challenged in court by the pharmaceutical industry trade association Pharma. The AG reports that Pharma has an apparent policy of mounting judicial challenges to any and all state designed programs intended to lower the price of prescription drugs to consumers.
FISCAL IMPLICATIONS
The bill does not
contain an appropriation. (See administrative implications below)
ADMINISTRATIVE IMPLICATIONS
HSD estimates the
staffing for a dedicated prior approval unit of 3 to 5 technician full time
equivalents (FTEs) and 1 to 2 pharmacist FTEs. Greater economies of scale might be achieved through contracting
out to an existing prior approval system.
Two possibilities are the Medicaid Utilization Review Unit at Blue Cross
Blue Shield (BCBS) in Albuquerque and the prescription drug card system prior
approval unit with Affiliated Computer System (ACS) in Atlanta. The ACS Prior Authorization (PA) unit is
staffed by pharmacists and technicians and performs New Mexico Medicaid’s
point-of-sale pharmacy claims processing from the same campus. The Albuquerque-based BCBS unit is staffed
by nurses and a medical director and has a less direct link into the Medicaid
claims processing system.
Employing
a drug formulary would require the creation of a Pharmacy and Therapeutics
(P&T) Committee as outlined in the Social Security Act, Section 1927. Additional staffing would be needed for
clerical support.
Staffing
resources will be required for the hearings and independent auditors may be
necessary to monitor the program.
RELATIONSHIP
TECHNICAL ISSUES
Amend Section 6B to
“The Department shall not impose transaction charges, beyond those normally
charged by other point-of-sale adjudication systems, on wholesalers or
participating retail pharmacies that submit claims under the program." The
department proposes the above amendment because if a transaction charge is not
imposed as indicated in Section 6B,
the fees normally charged by claims processors to pharmacies (about $0.12 for
each claim transmitted, regardless of adjudication outcome), may have to be
absorbed through the rebates, reducing the net cost savings by a corresponding
amount.
OTHER SUBSTANTIVE ISSUES
HSD identifies the
following as significant issues: the cost and logistics of outreach, auditing
and hearing mechanisms, maintaining the formulary, and the prior authorization
system. Moreover, HSD reports that SB 238
could cause buy-in and profitability concerns by pharmacies, opposition from
medical providers, patients, advocacy groups, and drug companies. Further, HSD believes that SB 238 would
change the relationship of pharmacies to the Medicaid program and would affect
existing State contract with Express Scripts.
A
forthcoming Health Policy Commission survey of New Mexico households will
provide a better estimate of the total number of New Mexicans who have no
prescription drug coverage, as well as the number of those who are unable to
acquire necessary prescriptions. The
overall lack of coverage according to HPC is evidenced by the following
statistics:
HSD suggests that all State prescription drug
benefits management could be placed under a single administrative umbrella
(i.e., Medicaid and Risk Management, Retiree Health, teachers, etc.) if it turned
out to be a more efficient way to operate the programs.
BD/prr:ar
[1]Begin typing on the * in replace mode. Do not add or delete spaces.